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Abstract
 
Because of different cytokine responsiveness, surface receptor, and transcription factor expression,
human CD11c
 
 
 
 natural type I interferon–producing cells (IPCs) and CD11c
 
 
 
 dendritic cells
were thought to derive through lymphoid and myeloid hematopoietic developmental path-
ways, respectively. To directly test this hypothesis, we used an in vitro assay allowing simulta-
neous IPC, dendritic cell, and B cell development and we tested lymphoid and myeloid committed
hematopoietic progenitor cells for their developmental capacity. Lymphoid and common myeloid
and granulocyte/macrophage progenitors were capable of developing into both functional
IPCs, expressing gene transcripts thought to be associated with lymphoid lineage development,
and into dendritic cells. However, clonal progenitors for both populations were about fivefold
more frequent within myeloid committed progenitor cells. Thus, in humans as in mice, natural
IPC and dendritic cell development robustly segregates with myeloid differentiation. This would
fit with natural interferon type I–producing cell and dendritic cell activity in innate immunity,
the evolutionary older arm of the cellular immune system.
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development • hematopoietic lineage commitment
 
Introduction
 
Differentiation of hematopoietic stem cells (HSCs) to mature
cells of the hematopoietic system involves loss of the self-
renewal potential followed by sequential restriction of devel-
opmental options; i.e., the gradual commitment to different
hemato-lymphoid lineages. In both mice and man, non–
self-renewing progenitor cell populations with high expansion
potential into exclusively lymphoid or myeloid lineages were
identified, thus suggesting a lympho–myeloid dichotomy as
one of the earliest steps in this hierarchical differentiation
process (1).
DCs are cells of the hematopoietic system. Originally
defined by their capacity to initiate primary T cell responses
(2), DCs are also involved in maintaining peripheral toler-
ance and in regulating innate immunity (3, 4). Given their
importance in immune regulation, understanding develop-
ment and maintenance of DCs may thus lead to novel, tar-
geted therapies in conditions such as immune deficiencies
or autoimmune diseases.
Multiple subtypes of DCs that differ in phenotype, local-
ization in lymphoid and nonlymphoid tissues, and in bio-
logical function have been described previously (3). With
the exception of subpopulations such as epidermal Langerhans
cells, DCs are continuously replenished from bone marrow
HSCs. In vitro, human DCs can be generated from CD34
 
 
 
hematopoietic precursor cells and from monocytes (5–7).
In addition, it was shown recently that type I interferon–
producing cells (IPCs) are capable of maturing to DCs (also
called plasmacytoid DCs), at least in vitro (8, 9). IPCs can
be generated from CD34
 
 
 
 hematopoietic progenitors (10–
13). Although CD34
 
 
 
 cells expand and require proliferative
and inflammatory stimuli to differentiate into DCs, mono-
cytes and IPCs show little or no proliferative capacity, and
DC maturation is triggered by distinct survival and inflam-
matory signals (3, 9, 14, 15).
IPCs and their offspring, mature DCs, display the follow-
ing features commonly associated with lymphoid, but not
myeloid, cell lineages: IPCs express CD2, CD5, and CD7
(3); T cell development associated pre-TCR
 
 
 
 transcripts
(12, 16, 17); B cell development associated Ig
 
 
 
-like 14.1;
and Spi-B (17, 18). Furthermore, IPCs lack markers as
CD11c, CD13, CD33 and mannose receptors (3); GM-CSF
does not promote IPC and plasmacytoid DC development
(11, 19); and differentiation of IPCs and B cells but not
CD11c
 
 
 
 dendritic cells is inhibited by ectopic expression of
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inhibitor of DNA binding Id2 and Id3 (12). Thus, it was
suggested that IPCs and their offspring CD11c
 
 
 
 plasmacy-
toid DCs segregate with early lymphoid development and
therefore are lymphoid lineage derived (3, 12).
To formally test this hypothesis, we used human early
lymphoid and myeloid committed progenitor cells (20, 21)
and evaluated their developmental potential in an assay sys-
tem simultaneously promoting IPC, CD11c
 
 
 
 DC, and B
cell differentiation.
 
Materials and Methods
 
Cell Samples.
 
Cord blood from healthy full-term newborns
was obtained with written informed parental consent. The use of
cord blood was approved by the Cantonal Ethics Board of Ti-
cino, Switzerland. Peripheral blood mononuclear cells were ob-
tained from healthy blood donors.
 
Cell Preparation and Flow Cytometry.
 
Mononuclear cells were
isolated by density gradient centrifugation (Ficoll-Paque; ICN
Biomedicals). CD34
 
 
 
 cells were immunomagnetically enriched
according to the manufacturer’s instructions (CD34
 
 
 
 selection
kit; Miltenyi Biotec). Hematopoietic progenitor cells were iso-
lated as described previously (20, 21). In brief, combined HSCs
and progenitors were sorted as lin
 
 
 
 (CD2, RPA-2.10; CD3,
S4.1; CD4, S3.5; CD8, 3B5; CD11b, ICRF44; CD14, TUK4;
CD19, SJ25-C1; CD20, 2H7; CD56, B159; and GPA, GA-R2)
CD34
 
 
 
 (HPCA-2) IL-3R
 
 
 
 
 
/
 
 
 
 (CD123, 9F5) cells. Lymphoid
committed cells were sorted as lin
 
 
 
CD34
 
 
 
CD38
 
 
 
 (HIT2) CD10
 
 
 
(5-1B4) and/or CD7
 
 
 
 (CD7-6B7). Myeloid committed cells
were sorted as lin
 
 
 
 (as aforementioned with the addition of
CD7 and CD10) CD34
 
 
 
CD38
 
 
 
, and IL-3R
 
 
 
 
 
 (CD123, 9F5)
CD45RA
 
 
 
 (MEM56) (common myeloid progenitors [CMPs]), or
IL-3R
 
 
 
 
 
CD45RA
 
 
 
 (granulocyte/macrophage progenitors [GMPs]),
or IL-3R
 
 
 
 
 
CD45RA
 
 
 
 (megakaryocyte/erythrocyte progenitors
[MEPs]). When lymphoid and myeloid progenitor cells were
sorted simultaneously from the same cord blood sample,
CD45RA was omitted from the staining, and CMP and GMP
were sorted as a combined cell population. In all cases, IL-3R
 
 
 
hi
 
cells were carefully excluded. Antibodies against the following
antigens were used as indicated: CD11c (B-ly6), HLA-DR
(TÜ36), TLR-2 (TL2.1), TLR-4 (HTA125), CD3 (UCHT1),
CD14 (RM052), CD40 (MAB89), CD62L (DREG56), CD80
(MAB104), CD83 (HB15a), CD86 (HA5.2B7), CD4 (13B8.2),
CD19 (J4.119), BDCA-1 (AD5-8E7), BDCA-2 (AC144), and
BDCA-4 (AD5-17F6). Antibodies were purchased from BD
Biosciences, Caltag, Ancell, Miltenyi Biotec, or Immunotech.
Dead cells were excluded by propidium iodide staining and ap-
propriate isotype-matched control mAbs were used to determine
the level of background staining. Cells were sorted and analyzed
using a 488-nm argon and a 633-nm helium-neon laser FACS
Vantage SE (Becton Dickinson). For single cell and limiting dilu-
tion assays, cells were double sorted to achieve virtually pure cell
populations.
 
Cell Culture.
 
Cells were cultured for 10–20 d on irradiated
(30 Gy) murine Sys-1 (Ac6) (SyStemix Inc.) stroma cell mono-
layers in RPMI 1640 (GIBCO BRL) supplemented with 100 U/ml
penicillin/streptomycin, 100 U/ml 
 
l
 
-glutamine, 20 nM 2-mer-
captoethanol, 10% FCS (GIBCO BRL), and 10 ng/ml recombi-
nant human flt3 ligand (R&D Systems).
To determine cellular divisions in culture, input populations
were labeled for 10 min with 5 
 
 
 
M carboxyfluorescein diacetate
succinimidyl ester (CFSE; Molecular Probes) at 37
 
 
 
C.
For limiting dilution experiments, cells were sorted directly
into 96-well plates on irradiated stroma cells at numbers of 300,
100, 30, 10, and 1 cell per well. Frequency of progenitors reading-
out as both IPC and DC was determined using “Loi de Poisson”
statistics. The percentage of detection failure for both IPCs and
DCs was calculated as 100 
 
 
 
 (1 
 
 
 
 k/n), where k
 
 
 
is the
 
 
 
number of
positive wells for both cell types, and n
 
 
 
is the number of repeats.
To generate DCs from monocytes, immunomagnetically se-
lected (Miltenyi Biotec) peripheral blood CD14
 
 
 
 cells were cul-
tured in RPMI 1640 supplemented with 10% FCS, 100 ng/ml
GM-CSF (Leukomax; Novartis), and 20 ng/ml human IL-4
(R&D Systems) over 5 d.
For DC maturation, 0.1 
 
 
 
g/ml LPS (Sigma-Aldrich) was
added to CD34
 
 
 
 and monocyte-derived DC cultures overnight.
Mixed lymphocyte reactions were performed using CFSE-
labeled CD4
 
 
 
 peripheral blood responder T cells plated with
stimulator cells in U-bottom 96-well plates in a 10:1 ratio.
 
Cytospin Preparations.
 
Cells were spun on microscope slides and
were fixed and stained with May-Grünwald and Giemsa’s reagent.
 
INF-
 
 
 
 Production.
 
Sorted cells were infected overnight with
40 HAU/ml of Influenza virus (strain A/Beijing/353/89, gift of
I. Julkunen) in U-bottom 96-well plates and INF-
 
 
 
 was mea-
sured in supernatants (human INF-
 
 
 
 ELISA kit, PBL Biomedical
Laboratories).
 
PCR Analysis.
 
RNA was isolated from sorted cells using
TRIzol reagent (Invitrogen) followed by DNase I (Invitrogen)
treatment. cDNA was synthesized using random hexamers and
Superscript II reverse transcriptase (Invitrogen).
Real-time PCR was performed using a sequence detector
(model ABI PRISM 7700; PerkinElmer) and TaqMan target
mixes (Assay-on-Demand Gene expression reagents; Applied Bio-
systems): Flt3 (Hs 00174690 m1), c-mpl (Hs 00180489 m1), IL-7R
 
 
 
(Hs 00233682 m1), pre-TCR
 
 
 
 (Hs 00300125 m1), Spi-B (Hs
00162150 m1), and 
 
 
 
-actin (Hs 99999903 m1). TLR transcripts
were detected using the following primer and probe sequences:
TLR2 (F, CAGCACTGGTGTCTGGCATG; Probe, CTGTG-
CTCTGTTCCTGCTGATCCTGC; and R, GAGCCAGGC-
CCACATCATT), TLR4 (F, GTTTCCTGCAATGGATCAA-
GGA; Probe, TCGTTCAACTTCCACCAAGAGCTGCCT; and
R, TGCTTATCTGAAGGTGTTGCACAT) TLR7 (F, TTA-
CCTGGATGGAAACCAGCTACT; Probe, AGATACCG-
CAGGGCCTCCCGC; and R, TCAAGGCTGAGAAGCTG-
TAAGCTA), TLR9 (F, TGAAGACTTCAGGCCCAACTG;
and Probe, AGCACCCTCAACTTCACCTTGGATCT-
GTC).
 
Results and Discussion
 
We wanted to test CD11c
 
 
 
 IPC and CD11c
 
 
 
 DC differ-
entiation from human lineage–restricted hematopoietic pro-
genitor cells (20, 21) to clarify their respective lymphoid
and/or myeloid lineage–associated developmental pathways.
Under the influence of GM-CSF, human CD34
 
 
 
 he-
matopoietic cells and monocytes give rise to CD11c
 
 
 
 DCs
in culture (5–7). Also, using multiple cytokines, it was
shown that lymphoid progenitors differentiate into DCs,
albeit with lower efficiency (20, 22). We cultured sorted
human CMPs, GMPs, and MEPs in complete media sup-
plemented with SCF, Flt3L, GM-CSF, IL-4, and TNF
 
 
 
.
CMPs and GMPs expanded 40–50-fold; and at 2 wk,
about half of cells in culture displayed DC morphology, 
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expressed CD11c, MHC class II, CD40, CD80, CD83,
and CD86, and were efficient stimulators in allogeneic
mixed lymphocyte reactions (unpublished data). No CD11c
 
 
 
DCs developed from MEPs, and no CD11c
 
 
 
IL3R
 
 
 
hi
 
 IPCs
were detectable from any of the progenitor populations
(unpublished data).
However, IPCs differentiate from human CD34
 
 
 
 cells
in Flt3L-supplemented cultures within 10–25 d (11, 13)
and on S17 stroma cells within 4 d (12). We found that
sorted lin
 
 
 
CD34
 
 
 
IL-3R
 
 
 
 
 
/lo
 
 cells cultured for 8–20 d on
Ac6 stroma cells supplemented with 10 ng/ml Flt3L gave
rise to both CD11c
 
 
 
IL-3R
 
 
 
hi
 
 (5–29% of total cells) and
CD11c
 
 
 
IL-3R
 
 
 
lo
 
 cells (3–14%; Fig. 1 A). To acquire IPC
and DC phenotypes, input cells divided five to six times
(Fig. 1 B). CD11c
 
 
 
IL-3R
 
 
 
hi
 
 cells coexpressed HLA-DR,
CD86, CD45RA, CD62L, and BDCA-2, but not CD80,
CD83, CD40, and CD34 (Fig. 1 C), and, after overnight
stimulation with influenza virus, produced similar amounts
of INF
 
 
 
 as peripheral blood BDCA-4
 
 
 
 IPCs (Fig. 1 D).
Thus, culture-generated CD11c
 
 
 
IL-3R
 
 
 
hi
 
 cells are func-
tional IPCs. CD11c
 
 
 
IL-3R
 
 
 
lo
 
 cells coexpressed HLA-DR,
CD86, CD40, CD45RA, TLR2, TLR4, and BDCA-1,
but not CD80, CD83, and CD34, which is consistent with
an immature CD11c
 
 
 
 DC phenotype (Fig. 1 C). After
overnight activation with LPS, cells up-regulated CD80
and CD83, acquired typical DC morphology (Fig. 1 E and
not depicted), and became potent stimulators of allogeneic
T cells (Fig. 1 F). Thus, culture-generated CD11c
 
 
 
 IL-
3R
 
 
 
lo
 
 cells are functional immature DCs.
Ac6 cells produce mouse stem cell factor (SCF), flt3L,
IL-7, and IL-15, and supported human IPC, DC, as well as
B cell differentiation (unpublished data). However, addition
of 10 ng/ml human flt3L led to an about threefold increase
of total cell numbers without obviously changing the per-
centage of differentiated cell fractions (unpublished data).
Therefore, this culture system provides a tool to simulta-
neously evaluate IPC, DC, and B cell differentiation from
defined human hematopoietic progenitor cells in vitro.
Lymphoid progenitors, CMPs, and GMPs (as well as
combined CMP and GMP) gave rise to both CD11c
 
 
 
IL-
3R
 
 
 
hi
 
 and CD11c
 
 
 
IL-3R
 
 
 
lo
 
 cells (Fig. 2 A); however, the
mean expansion of CMPs and GMPs was higher than that
of lymphoid progenitors (Table I). CD11c
 
 
 
IL-3R
 
 
 
hi
 
 cells
derived from either progenitors produced high amounts of
Figure 1. Lin CD34 IL3R lo
cells develop in vitro to functional
IPCs and immature DCs. (A)
Sorted lin CD34 IL3R lo cells
develop to both CD11c IL3R hi
and CD11c IL3R lo cells within
13 d and (B) five to six divisions
of input cells as determined by
CFSE dilution in flt3L-supple-
mented Ac6 stroma cell cul-
tures. Percentages of gated pop-
ulations are indicated in contour
plots. (C) CD11c IL3R hi and
CD11c IL3R lo cells express
IPC- and DC-associated sur-
face markers (bold lines) on in-
dicated cell populations as gated
in A. (D) Influenza-stimulated
CD11c IL3R hi cells but not
CD11c / IL3R lo/  cells from
culture produce similar amounts
of IFN  as peripheral blood
BDCA-4  IPCs. Mean and stan-
dard deviation of 10 (cultured
cells) and 5 (BDCA-4  cells)
experiments are shown. (E) LPS-
activated CD11c IL3R lo cells
up-regulate CD80 (bold line),
show typical DC morphology,
and (F) are potent stimulators of
allogeneic CD4  T cells as de-
termined by CFSE dilution at
day 7. Contour plot shows overlay
of CD3  gated T cell prolifera-
tion in response to activated
CD11c IL3R lo cells (bold line),
CD14  monocyte-derived den-
dritic cells (thin line), and CD11c 
cells (dashed line). Cells were
plated in a 1:10 stimulator to re-
sponder cell ratio. Data are rep-
resentative of two experiments.Human Type I Interferon–producing Cell and Dendritic Cell Development 1522
IFN  upon viral stimulation, thus were functional IPCs
(two experiments each: 4,100 and 1,440 pg IFN /ml/104
CD11c IL-3R hi cells from lymphoid progenitors; and
3,470 and 1,720 pg IFN /ml/104 CD11c IL-3R hi cells
from CMPs and GMPs). Similarly, lymphoid- and my-
eloid-derived CD11c  cells became functional DCs after
overnight LPS maturation, as determined by surface marker
expression and capacity to stimulate allogeneic T cells
(unpublished data). MEPs showed only limited, if any,
CD11c IL-3R hi cell differentiation capacity and did not
generate CD11c IL-3R lo cells (Fig. 2 A), demonstrating
that, as in mice (23), DC differentiation potential is lost,
once megakaryocyte/erythrocyte commitment occurs. As
demonstrated previously (21), myeloid progenitors did not
differentiate into B cells, whereas lymphoid progenitors si-
multaneously generated IPCs, DCs, and B cells (Fig. 2 A).
In limiting dilution analysis,  1 out of 92 lymphoid pro-
genitors and 1 out of 18 combined CMP and GMP progen-
itors gave rise to both IPCs and DCs (Fig. 2, B and C).
These data prove that both lymphoid- and myeloid-com-
mitted cell populations contain single cells with IPC and DC
potential, and shows that these progenitors are more fre-
quent within myeloid committed cell populations, at least as
detected by this in vitro assay. Although no single lymphoid
progenitor cell simultaneously generated IPCs, DCs, and B
cells, clonal IPC/B and DC/B progenitors were detectable
(3 in 168, and 4 in 168, respectively). Thus, the lack of com-
bined IPC, DC, and B cell read out from single lymphoid
progenitors might be caused by lineage determination before
the second cell division in culture.
To evaluate gene transcripts associated with IPC and DC
development, we tested mRNA expression in progenitor
cells and in their respective differentiated IPC and DC cell
fractions (Fig. 3). Flt3 was expressed in combined CMPs
and GMPs at high levels, in lymphoid progenitors and both
offspring IPCs at intermediate levels, and in both offspring
DCs at low, but still, detectable levels (Fig. 3), thus likely
paralleling mouse flt3 expression in IPC and DC develop-
ment (24, 25). To formally prove this, progenitors should
be isolated according to surface flt3 expression. However,
currently available monoclonal antibodies to human flt3 in
our hands did not provide sufficient discrimination of pop-
ulations to directly address this issue. In contrast to flt3,
trombopoietin (Tpo) receptor transcripts (c-mpl) were only
Figure 2. Lymphoid progenitors, CMPs, and GMPs develop in vitro
to both IPCs and immature DCs and contain clonal progenitors for
both populations. (A) Lymphoid progenitors, CMPs, and GMPs gener-
ate comparable relative numbers of both CD11c IL3R hi and CD11c 
IL3R lo cells, whereas MEPs generate few, if any, CD11c IL3R hi and
no CD11c IL3R lo cells (top). Only lymphoid progenitors developed
to CD19  B cells (bottom). Representative contour plots of three exper-
iments analyzed at day 14 of culture. (B) Frequencies of myeloid (solid
line) and lymphoid (dashed line) progenitors simultaneously differenti-
ating to IPCs and DCs were determined by limiting dilution. The x
axis depicts the number of plated cells and the y axis detection failure
for combined IPC and DC read-out. Horizontal and vertical bars mark
the 37% negative read-out predicting progenitor frequencies (numbers
in brackets). Statistics were calculated on the basis of mean values of
each dilution step from three and six independent experiments for my-
eloid and lymphoid progenitors, respectively. Correlation coefficients
for curve extrapolations were r   0.9372 and r   0.93996 for myeloid
and lymphoid progenitors, respectively. (C) Dot plot shows typical
combined IPC and DC read-out from a single myeloid progenitor at
day 14 d of culture. Percentages of gated populations are indicated in
all plots.
Table I. Cellular Expansion of CD34  IL-3R lo Cells and Lymphoid and Myeloid Progenitors
Total IPCs DCs
CD34  IL-3R lo 129.7 (96–160) 18.5 (10.6–29.7) 10.4 (8.6–13.5)
CMPs and GMPs 55.8 (30–88) 5.5 (0.9-12) 5.2 (1.8–14.9)
Lymphoid progenitors 24.9 (10–60) 2.7 (0.6–8.9) 3.9 (1.0–9.9)
Mean fold expansion of total cells, IPCs and DCs relative to input progenitor cell numbers at day 13 of cultures. Numbers in parentheses represent
the range. Data represent results from three independent experiments for CD34  IL-3R lo cells, nine for CMPs and GMPs, and seven for lymphoid
progenitors. Chicha et al. Brief Definitive Report 1523
detectable on progenitors (Fig. 3), thus suggesting that IPC
gain in flt3L- and Tpo-supplemented CD34  cell cultures
is rather a result of Tpo-driven progenitor cell expansion
than of Tpo-mediated IPC differentiation signals (13).
Expression of lymphoid-associated transcripts as pre-T 
and Spi-B was taken as evidence for lymphoid lineage der-
ivation of IPCs (3, 12, 16, 17). Interestingly, both lym-
phoid– and myeloid progenitor–derived IPCs expressed
the lymphoid-associated transcripts pre-T , IL-7R , and
Spi-B, albeit at slightly different levels (Fig. 3). Thus, al-
though some of these transcripts are likely biologically rele-
vant for IPC development and function (18), they do not
allow conclusions on hematopoietic lineage origin.
Both lymphoid and myeloid progenitor derived IPCs ex-
pressed TLR7 and TLR9 and both DCs expressed TLR2,
4, and 7 as described previously (3, 14, 15) and low level
expression of some TLRs could be detected in progenitor
populations. Because TLR ligation provides important cues
for IPC and DC maturation and function, it is tempting to
speculate that TLR ligation might influence early IPC and
DC differentiation, e.g., in inflammatory conditions.
Together, our data demonstrate that both human IPCs
and DCs develop from lymphoid- and myeloid-restricted
progenitor cells. Compared with lymphoid progenitors,
myeloid progenitors are 5–10-fold more abundant in cord
blood and bone marrow (20–22). As shown here, clonal
progenitors for both IPCs and DCs are more frequent in
myeloid populations and, on a population basis, myeloid
progenitors show higher expansion potential for both IPCs
and DCs. Therefore, if IPC, DC, and B cell read out in this
bone marrow stroma cell culture truly reflects in vivo
steady-state IPC, DC, and B cell development, most IPCs
and DCs should be derived from myeloid progenitor pop-
ulations, at least in the extrathymic environment. This par-
allels our and others previous findings for in vitro and in
vivo CD11c  DC and IPC development in mice (23, 26,
27; unpublished data), suggesting that these pathways are
conserved in different species.
Recently, a dividing precursor population for IPCs and
DCs was characterized in mouse blood (28); clonal analysis
to test the existence of single cells with multi-DC differenti-
ation capacities, however, were not provided. Here, we
demonstrate for the first time clonal precursors for both
IPCs and DCs in lymphoid and myeloid progenitor cell
populations; however, the question of a possible down-
stream IPC- and DC-restricted clonal progenitor is not ad-
dressed. We reason that promiscuous IPC and DC poten-
tials in successive hematopoietic differentiation correlates
with expression and responsiveness to flt3/flt3L signals and
likely are terminated by concurring lineage determination
events (e.g., expression of Pax5 in B cell differentiation [ref-
erence 29]). This should be tested in future experiments.
IPCs, and to some extent CD11c  DCs, are important
mediators of innate immunity, and, after consecutive matura-
tion, initiate antigen-specific adaptive immune responses.
However, innate immunity predates adaptive immunity in
evolution. In this view, it is conceivable that both IPC and
DC differentiation robustly segregates with myeloid develop-
ment; then, IPCs might primarily use genetic programs that
later were adopted in adaptive immune system development.
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